symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GOVX,0.539,2.968199,380875,14253100,0,0.505-1.39,0.0026,"GeoVax Labs, Inc.",USD,0000832489,US3736785078,373678507,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.geovax.com,"GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.",Mr. David Alan Dodd,Healthcare,US,14,678 384 7220,1900 Lake Park Drive,Smyrna,GA,30080,1.87281,2.98281,https://financialmodelingprep.com/image-stock/GOVX.png,2020-09-25,False,False,True,False,False
